Evorpacept + Trastuzumab + Chemotherapy (ASPEN-09)
HER2+ Breast Cancer
Phase 1Recruiting
Key Facts
About ALX Oncology
ALX Oncology is a clinical-stage biotech focused on developing evorpacept, a next-generation CD47 inhibitor engineered to minimize toxicity while promoting macrophage-mediated tumor destruction. The company's core strategy is to develop evorpacept as a synergistic backbone therapy in combination with established and emerging oncology agents, with multiple Phase 2 trials underway. Key achievements include establishing proof-of-concept in gastric cancer and securing strategic collaborations with major pharmaceutical partners to expand its clinical reach.
View full company profileTherapeutic Areas
Other HER2+ Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| PYTX-004 | Papyrus Therapeutics | Preclinical |
| T-siHER2-NP™ | Pdx Pharmaceuticals | Preclinical |
| Pyrotinib (SHR-1258) | Jiangsu Hengrui Medicine | Approved |
| Biosimilar to Trastuzumab | Shenzhen Salubris Pharmaceuticals | Phase III |
| Phesgo® (with Roche) | Halozyme Therapeutics | Approved |